Idraparinux sodium

Drug Profile

Idraparinux sodium

Alternative Names: Idraparinux; SANORG 34006; SR 34006

Latest Information Update: 20 Oct 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Organon
  • Developer sanofi-aventis
  • Class Anticoagulants; Antithrombotics; Oligosaccharides
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 04 Jan 2007 Data presented at the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH-2006) added to the Thromboses therapeutic trials section
  • 12 Sep 2005 sanofi-aventis has ceased enrolment in the AMADEUS trial for the prevention of venous thromboembolism in patients with atrial fibrillation
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top